Asian Pacific Journal of Cancer Prevention

  • 제17권1호
  • /
  • Pages.235-238
  • /
  • 2016
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Incidence of Active HCV infection amongst Blood Donors of Mardan District, Pakistan

  • Karim, Fawad (Department of Biotechnology, Bacha Khan University Charsadda) ;
  • Nasar, Abu (Department of Biotechnology, Bacha Khan University Charsadda) ;
  • Alam, Ibrar (Department of Biotechnology, Bacha Khan University Charsadda) ;
  • Alam, Iftikhar (Department of Human Nutrition and Dietetics (HND), Bacha Khan University Charsadda) ;
  • Hassan, Said (Center of Biotechnology and Microbiology, University of Peshawar) ;
  • Gul, Rahmat (Department of Human Nutrition and Dietetics (HND), Bacha Khan University Charsadda) ;
  • Ullah, Sana (Department of Animal Science Quaid-i-Azam University Islamabad) ;
  • Rizwan, Muhammad (Center of Biotechnology and Microbiology, University of Peshawar)
  • 발행 : 2016.02.05
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Hepatitis C is an ailment of liver caused by hepatitis C virus (HCV) infection. About 3% of the world population is infected by this virus. HCV infection is a leading reason for liver cirrhosis and therefore a major source of hepatocellular carcinoma. The study focused on the incidence of active HCV infection in blood donors of Mardan district of KPK, Pakistan. A total of 5318 blood donors were inspected for the presence of anti-HCV antibodies and HCV-RNA using ICT (immune-chromatographic test), ELISA and RT-PCR at Mardan Medical Complex (MMC), Mardan. Out of these, 157 (2.95%) were positive by ICT, 60 (1.12%) by ELISA and 56 (1.05%) for HCV-RNA. The frequency of active HCV infectivity amongst the blood donors from district Mardan, KPK Pakistan was 1.05 %. Application of strict measures during blood donor selection and use of proper screening assays such as ELISA in place of ICT devices can give a more accurate picture so that the incidence of this viral infection in HCV negative blood recipients can be reduced.

키워드

참고문헌

  1. Afridi SQ, Ali MM, Awan F (2015). Molecular epidemiology and viral load of HCV in different regions of Punjab, Pakistan. J Hepatol, 62, 1256-64. https://doi.org/10.1016/j.jhep.2015.01.011
  2. Ahmed A, (2006). Anti-HCV in healthy voluntary blood donors in district Swat. J Postgrad Med Inst, 20, 187-90.
  3. Ahmad J, Taj AS, Rahim A, et al (2004). Frequency of Hepatitis B and Hepatitis C in healthy blood donors of NWFP a single center experience. J Postgrad Med Inst, 18, 343-52.
  4. Akhtar S, Moatter T, (2004). Hepatitis C virus infection in polytransfused thalassemic children in Pakistan. Indian Pediatrics, 41, 1072-3.
  5. Ahmad A, Ahmad B, Ali A, et al (2009). Seroprevalence of HBsAg and anti HCV in general healthy population of Swat district with frequency of different HCV Genotypes. Pakistan J Med Sci, 25, 744-748.
  6. Ahmad B, Ali S, Ali I, Azam S, Bashir S (2012). Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK). Virol J, 9, 18. https://doi.org/10.1186/1743-422X-9-18
  7. Akhtar N, Bilal M, Rizwan M, et al (2015). Genotypes of Hepatitis C Virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan. Asian Pac J Cancer Prev, 16, 1037-40. https://doi.org/10.7314/APJCP.2015.16.3.1037
  8. Ajaccio BM, Sandra CF, (2002). Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study. BMC Gastroenterol, 2, 18. https://doi.org/10.1186/1471-230X-2-18
  9. Alam I, Alam I, Ali I, et al (2014). Weight loss in HCV patients can be used as a surrogate marker for evaluation of interferon (IFN-${\alpha}$) treatment efficacy - A prospective pilot study. Pak J Pharm Sci, 27, 571-6.
  10. Alter MJ (2007). Epidemiology of hepatitis C virus infection. World J Gastroenterol, 13, 2436-41. https://doi.org/10.3748/wjg.v13.i17.2436
  11. Bangash MH, (2009). Prevalence of hepatitis B and hepatitis C among healthy blood donors at Kurram agency. J Postgraduate Med Inst, 23, 140-5.
  12. Bruggmann P (2014). Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepatitis, 21, 5-33.
  13. Grobusch MP, Alpermann U, Schwenke S, et al (1999). False positive rapid tests for malaria in patients with rheumatoid factor. Lancet, 3, 353-297.
  14. Ijaz Ali, Lubna Siddique, et al (2011). Prevalence of HCV among the high risk groups in Khyber Pakhtunkhwa .Virol J, 8, 296. https://doi.org/10.1186/1743-422X-8-296
  15. Kato N (2000). Genome of human hepatitis C virus (HCV), gene organization, sequence diversity, and variation. Microbial and Comparative Genomics, 5, 129-51. https://doi.org/10.1089/omi.1.2000.5.129
  16. Khan MSA, Khalid M, Ayub N, et al (2004). Seroprevalence and risk factors of Hepatitis C virus (HCV) in Mardan, NWFP. Rawal Med J, 29, 57-60.
  17. Khattak MN, Akhtar S, Mahmud S, (2008). Factors influencing hepatitis C virus sero-prevalence among blood donors in north west pakistan. J Public Health Policy, 29, 207-25. https://doi.org/10.1057/jphp.2008.7
  18. Moyer LA, Mast EE, Alter MJ, et al (1999). Hepatitis C, routine serologic testing and diagnosis. Am Fam Physician, 59, 79-88.
  19. Mujeeb SA, Pearce MS, (2008). Temporal trends in hepatitis B and C infection in family blood donors from interior Sindh, Pakistan. Biomed Central Infectious Diseases, 8, 43.
  20. Munaf A, Memon MS, Kumar P, Ahmed S, Kumar MB (2014). Comparison of viral hepatitis-associated hepatocellular carcinoma due to HBV and HCV - cohort from liver clinics in Pakistan. Asian Pac J Cancer Prev, 15, 7563-7. https://doi.org/10.7314/APJCP.2014.15.18.7563
  21. Ozaras R, Tahan V (2009). Acute hepatitis C prevention and treatment. Expert Review Anti- Infective Therapy, 7, 351-61. https://doi.org/10.1586/eri.09.8
  22. Srivastava AV, Czerska B, Williams C, et al (2009). High rates of false-positive hepatitis C antibody tests can occur after left ventricular assist device implantation. J Heart Lung Transplant, 28, 159-60.
  23. Tunio SA. 2013. Seroprevalence of Hepatitis B and Hepatitis C among blood donors in Hyderabad, Pakistan. Gomal J Med Sci, 1, 2.
  24. WHO:Diseases; HepatitisC. (http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index3.html), (Accessed in 2015).

피인용 문헌

  1. Detection of HCV Persistent Infections in the Dental Pulp: A Novel Approach for the Detection of Past and Ancient Infections vol.11, pp.10, 2016, https://doi.org/10.1371/journal.pone.0165272
  2. Hepatitis C Virus and Interferon-Free Antiviral Therapeutics Revolution: Implications for Pakistan vol.30, pp.4, 2017, https://doi.org/10.1089/vim.2016.0164
  3. Seroprevalence of Hepatitis C Virus among Blood Donors in Middle Eastern Countries: A Systematic Review and Meta-Analysis vol.19, pp.12, 2017, https://doi.org/10.5812/ircmj.58045
  4. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses vol.5, pp.4, 2018, https://doi.org/10.1098/rsos.180257
  5. Comparative Analysis of Electrochemiluminescence Assay and Chemiluminescent Microparticle Immunoassay for the Screening of Hepatitis C pp.0974-0449, 2018, https://doi.org/10.1007/s12288-018-0968-3